Dyne Therapeutics
DYN | NASDAQ
$16.70
-$0.46 (-2.68%)
At close: Nov 16, 2026, 4:00 PM ET
$16.75
+$0.05 (+0.30%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Dyne Therapeutics Company Profile
Company profile explainedCompany Profile
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| John G. Cox | Chief Executive Officer, President & Director |
| Alessandro Martuscelli | Chief Legal Officer |
| Erick J. Lucera | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer |
| Axel Wiest | Senior VP and Head of Portfolio Strategy & Operations |
| Douglas Kerr | Chief Medical Officer |
| James Bilotta | Chief Digital & Information Officer |
| Johanna Friedl-Naderer | Chief Commercial Officer |
| Lucia Celona | Chief Human Resource Officer |
| Oxana Beskrovnaya | Chief Innovation Officer |
| Rajesh Manchanda | Chief Technical Officer |
Dyne Therapeutics
| Country | United States |
| IPO Date | Sep 17, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 289 |
| CEO | John G. Cox |
Contact Details
1560 Trapelo Road Waltham,
Massachusetts 02451 United States
Stock Details
| Ticker Symbol | DYN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818794 |
| CUSIP Number | 26818M108 |
| ISIN Number | US26818M1080 |
| SIC Code | 2834 |
Recent News
- 5 days ago / globenewswire.comDyne Therapeutics to Participate in Upcoming Investor Conference
- 12 days ago / globenewswire.comDyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- 2 months ago / globenewswire.comDyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
- 2 months ago / seekingalpha.comDyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / globenewswire.comDyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
- 3 months ago / globenewswire.comDyne Therapeutics to Participate in Upcoming Investor Conferences
- 4 months ago / globenewswire.comDyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- 4 months ago / globenewswire.comDyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
- 4 months ago / globenewswire.comDyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
- 4 months ago / globenewswire.comDyne Therapeutics Announces Proposed Public Offering of Common Stock
Add to Watchlist
Select watchlists to add or remove DYN